E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Active Crohn's disease |
Actieve ziekte van Crohn |
|
E.1.1.1 | Medical condition in easily understood language |
Active Crohn's disease |
Actieve ziekte van Crohn |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this prospective open label study is to assess the ability of vedolizumab to promote clinical, endoscopic and histological remission in patients with active Crohn's disease in an 'early' and a 'late' disease population after 54 weeks of treatment. |
|
E.2.2 | Secondary objectives of the trial |
Measures of clinical disease activity (including clinical response and remission) over the 1 year study period will be described. The mucosal healing capacity of vedolizumab treatment will be observed by assessing the endoscopic and histopathologic response to treatment over the 1 year study period.
The additional endoscopic healing effect of dose intensification at month 6 will also be studied after approval of amendment 4 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Established diagnosis of ileal, ileocolonic or colonic Crohn’s disease with histopathological confirmation available in the record of the patient.
- Moderately to severely active CD (CDAI 220-450) with objective evidence of ulcerations visualized on endoscopy.
- Anti-TNF discontinued for at least 4 weeks from baseline
- May continue stable dose of conventional therapies for IBD including thiopurines, methotrexate and corticosteroids
-Age 18 to 80
- GROUP 1 (EARLY CD):
Diagnosis of CD < 24 months prior to enrollment
Demonstrated failure to respond to topical or systemic corticosteroids or intolerance to corticosteroids
or: need for 1 course of steroids since diagnosis
or: steroid dependency at any dose since diagnosis
or: need for early biological treatment per Investigator’s discretion even without prior steroid or thiopurine treatment.
and additionally, but not mandatory, lack of efficacy ofthiopurines or intolerance to thiopurines (any duration). Patients who are using thiopurines at screening must have used them for > 3 months (last 4 weeks at stable dose).
GROUP 2 (LATE CD)
Subjects has been treated with corticosteroids and demonstrated failure to respond to at least 3 months of thiopurines or intolerance to thiopurines and: failure to respond to at least 1 anti-TNF or intolerance to anti-TNF or loss of response to at least 1 anti-TNF.
|
|
E.4 | Principal exclusion criteria |
- previous exposure to any anti-integrin autibodies including vedolizumab, alpha 4 beta7 anti-bodies, beta7 antibodies, anti-MADCAM-1
- Contraindication for endoscopy.
- History of colonic dysplasia or colonic cancer
- Presence of stoma
- Subjects with a pouch
- Received other biologics within the last 4 weeks of baseline
- Early CD group: previous exposure to any anti-TNF
- use of 5-ASA or corticosteroid enemas/suppositories within 2 weeks of enrollment
- chronic hepatitis B or C infection
- Evidence of or treatment for C. difficile infection or other intestinal pathogen at screening within 4 weeks prior to enrollment
- Active or latent tuberculosis
- Conditions which in the opinion of the investigator may interfere with the subject’s ability to comply with the study procedures.
- Received any investigational drug in the past 30 days or 5 half-lives, whichever is longer.
- Positive PML subjective symptom checklist before enrollment.
- Subjects with known allergy or hyposensitivity to vedolizumab or its components
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the proportion of patients with clinical and endoscopic remission at Week 26 and 52-54, defined as CDAI of 150 or lower and SES-CD <4. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Proportion of patients with absence of ulcers at Weeks 26 and 52-54
- Proportion of patients with endoscopic response (SES-CD reduction by ≥ 50 %) at Weeks 26 and 52
- Proportion of patients with 25% and 75% reduction of SES-CD at Weeks 26 and 52
- Proportion of patients with clinical response (CDAI decrease of ≥ 70 points from baseline) at all time points
- Proportion of patients with clinical remission (CDAI <=150) at all time other points
- Proportion of patients with corticosteroid- free clinical remission (CDAI <=150) at all other time points
- Proportion of patients with normalized serum CRP at all time points
- Proportion of patients with no granulocytes in the biopsies at Weeks 26 and 52.
- Proportion of patients with 25%, 50% and 75% reduction in the Geboes histology score at Weeks 26 and 52.
- Proportion of patients with sustained clinical response (response at all time points after and on week 10)
- Proportion of patients with sustained clinical remission (remission at all time points after week 10)
- Proportion of patients with draining fistulas
- Proportion of patients that need to be hospitalized
- Quality of life measured by IBDQ and Euroquol
- Work productivity Index
- Serum concentrations of vedolizumab and antibodies to vedolizumab before every infusion
- Incremental mucosal healing effects of dose intensification to every 4 weeks vedolizumab in endoscopic non responers (SES-CD ≥ 50 %) at month 6 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
all time points, week 2, week 6, week 10 , week 14, week 22, week 26, week 30, week 38, week 46, week 52 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 18 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 25 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |